ArticleFrontiers in nutrition2026
Natural product FZJDXJ enhances CD8+ T-cell glycolysis to relieve exhaustion and augment antitumor immunity in HBV
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate whether Fuzheng Jiedu Xiaoji Formula (FZJDXJ) reverses immunosuppression in HBV? hepatocellular carcinoma (HCC) by reprogramming CD8? T-cell glycolysis and enhance antitumor immunity. Methods: A translational study was conducted with 80 HBV? HCC patients, Hepa1-6 tumor-bearing mouse models and Results: FZJDXJ increased peripheral CD8? T-cell frequency, downregulated exhaustion markers (PD-1/CTLA-4/TIM-3) and upregulated glycolysis-related metabolites in patients, with metabolites correlating with CD8? T-cell function. In mice, FZJDXJ suppressed tumor growth, enhanced tumor-infiltrating CD8? T-cell cytotoxicity and glycolytic flux (GLUT1/HK2/PFKFB3/PKM2 upregulation). Conclusion: FZJDXJ alleviates CD8? T-cell exhaustion by enhancing glycolysis to strengthen antitumor immunity in HBV? HCC. Immunometabolism is a promising target for herbal interventions, and glycolysis-immune features may serve as prognostic stratifiers. Prospective trials and ICI combination studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.